Search hospitals > Pennsylvania > Pittsburgh

UPMC-Saint Margaret

Claim this profile
Pittsburgh, Pennsylvania 15215
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Recurrence
156 reported clinical trials
23 medical researchers
Photo of UPMC-Saint Margaret in PittsburghPhoto of UPMC-Saint Margaret in Pittsburgh

Summary

UPMC-Saint Margaret is a medical facility located in Pittsburgh, Pennsylvania. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Recurrence and other specialties. UPMC-Saint Margaret is involved with conducting 156 clinical trials across 298 conditions. There are 23 research doctors associated with this hospital, such as Liza C. Villaruz, Adam Brufsky, MD, Melissa A. Burgess, and Dan P. Zandberg.

Area of expertise

1Cancer
Global Leader
UPMC-Saint Margaret has run 63 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Breast Cancer
Global Leader
UPMC-Saint Margaret has run 31 trials for Breast Cancer. Some of their research focus areas include:
ER positive
HER2 positive
HER2 negative

Top PIs

Clinical Trials running at UPMC-Saint Margaret

Breast Cancer
Prostate Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Cancer
Squamous Cell Carcinoma
Renal Cell Carcinoma
Oropharyngeal Carcinoma
Small Cell Lung Cancer
Oral Squamous Cell Carcinoma
Image of trial facility.

Durvalumab + Chemotherapy

for Breast Cancer

This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Image of trial facility.

Omitting Radiation Therapy

for Breast Cancer

This study is evaluating whether a type of radiation therapy may help prevent breast cancer from coming back.
Recruiting2 awards Phase 319 criteria
Image of trial facility.

T-DM1 + Tucatinib

for Breast Cancer

This study is evaluating whether a combination of two drugs may help prevent breast cancer from coming back.
Recruiting1 award Phase 313 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at UPMC-Saint Margaret?
UPMC-Saint Margaret is a medical facility located in Pittsburgh, Pennsylvania. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Recurrence and other specialties. UPMC-Saint Margaret is involved with conducting 156 clinical trials across 298 conditions. There are 23 research doctors associated with this hospital, such as Liza C. Villaruz, Adam Brufsky, MD, Melissa A. Burgess, and Dan P. Zandberg.